Lantern Pharma Inc. (LTRN) - Total Debt to Equity Ratio

Lantern Pharma Inc. (LTRN) develops AI solutions to combat lung cancer. This daily price chart with the 0.00 indicator reflects the company's financial standing. The business relies on FDA approvals, which ensures immunity to seasonal fluctuations. Furthermore, biotechnology development follows its own cycle, transforming the asset into a defensive tool that remains independent of global economic downturns.

The specific operational model of Lantern Pharma Inc. (LTRN), characterized by the outsourcing of molecule synthesis and testing, necessitates rigorous control over financial stability to minimize risks associated with third-party vendor dependency. By analyzing the leverage ratio—the relationship between total debt and equity—investors assess the proportion of borrowed funds within the asset structure, where a sharp increase in this metric relative to revenue signals a critical level of indebtedness and a threat to liquidity.